Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes

Bora Inceoglu, Karen M. Wagner, Jun Yang, Ahmed Bettaieb, Nils H. Schebb, Sung Hee Hwang, Christophe Morisseau, Fawaz Haj, Bruce D. Hammock

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The nerve damage occurring as a consequence of glucose toxicity in diabetes leads to neuropathic pain, among other problems. This pain dramatically reduces the quality of life in afflicted patients. The progressive damage to the peripheral nervous system is irreversible although strict control of hyperglycemia may prevent further damage. Current treatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity of the pain state. However, available therapeutics have drawbacks, arguing for the need to better understand the pathophysiology of neuropathic pain and develop novel treatments. Here we demonstrate that stabilization of a class of bioactive lipids, epoxygenated fatty acids (EpFAs), greatly reduces allodynia in rats caused by streptozocin-induced type I diabetes. Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the levels of plasma and spinal EpFAs, respectively, and generated dose-dependent antiallodynic effects more potently and efficaciously than gabapentin. In acute experiments, positive modulation of EpFAs did not display differences in insulin sensitivity, glucose tolerance, or insulin secretion, indicating the efficacy of sEHIs are not related to the glycemic status. Quantitative metabolomic analysis of a panel of 26 bioactive lipids demonstrated that sEHI-mediated antiallodynic effects coincided with a selective elevation of the levels of EpFAs in the plasma, and a decrease in degradation products coincided with the dihydroxy fatty acids in the spinal cord. Overall, these results argue that further efforts in understanding the spectrum of effects of EpFAs will yield novel opportunities in treating neuropathic pain.

Original languageEnglish (US)
Pages (from-to)11390-11395
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number28
DOIs
StatePublished - Jul 10 2012

Fingerprint

Type 1 Diabetes Mellitus
Fatty Acids
Pain
Neuralgia
Lipids
Epoxide Hydrolases
Glucose
Metabolomics
Tricyclic Antidepressive Agents
Hyperalgesia
Peripheral Nervous System
Streptozocin
Hyperglycemia
Anticonvulsants
Opioid Analgesics
Insulin Resistance
Spinal Cord
Therapeutics
Quality of Life
Insulin

Keywords

  • Analgesic drug
  • Cytochrome P450
  • Glucose homeostasis
  • Motor depressant
  • Soluble epoxide hydrolase inhibitor

ASJC Scopus subject areas

  • General

Cite this

Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. / Inceoglu, Bora; Wagner, Karen M.; Yang, Jun; Bettaieb, Ahmed; Schebb, Nils H.; Hwang, Sung Hee; Morisseau, Christophe; Haj, Fawaz; Hammock, Bruce D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 28, 10.07.2012, p. 11390-11395.

Research output: Contribution to journalArticle

Inceoglu, Bora ; Wagner, Karen M. ; Yang, Jun ; Bettaieb, Ahmed ; Schebb, Nils H. ; Hwang, Sung Hee ; Morisseau, Christophe ; Haj, Fawaz ; Hammock, Bruce D. / Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 28. pp. 11390-11395.
@article{40183b1218c14fe799c75cc7018e3c99,
title = "Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes",
abstract = "The nerve damage occurring as a consequence of glucose toxicity in diabetes leads to neuropathic pain, among other problems. This pain dramatically reduces the quality of life in afflicted patients. The progressive damage to the peripheral nervous system is irreversible although strict control of hyperglycemia may prevent further damage. Current treatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity of the pain state. However, available therapeutics have drawbacks, arguing for the need to better understand the pathophysiology of neuropathic pain and develop novel treatments. Here we demonstrate that stabilization of a class of bioactive lipids, epoxygenated fatty acids (EpFAs), greatly reduces allodynia in rats caused by streptozocin-induced type I diabetes. Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the levels of plasma and spinal EpFAs, respectively, and generated dose-dependent antiallodynic effects more potently and efficaciously than gabapentin. In acute experiments, positive modulation of EpFAs did not display differences in insulin sensitivity, glucose tolerance, or insulin secretion, indicating the efficacy of sEHIs are not related to the glycemic status. Quantitative metabolomic analysis of a panel of 26 bioactive lipids demonstrated that sEHI-mediated antiallodynic effects coincided with a selective elevation of the levels of EpFAs in the plasma, and a decrease in degradation products coincided with the dihydroxy fatty acids in the spinal cord. Overall, these results argue that further efforts in understanding the spectrum of effects of EpFAs will yield novel opportunities in treating neuropathic pain.",
keywords = "Analgesic drug, Cytochrome P450, Glucose homeostasis, Motor depressant, Soluble epoxide hydrolase inhibitor",
author = "Bora Inceoglu and Wagner, {Karen M.} and Jun Yang and Ahmed Bettaieb and Schebb, {Nils H.} and Hwang, {Sung Hee} and Christophe Morisseau and Fawaz Haj and Hammock, {Bruce D.}",
year = "2012",
month = "7",
day = "10",
doi = "10.1073/pnas.1208708109",
language = "English (US)",
volume = "109",
pages = "11390--11395",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "28",

}

TY - JOUR

T1 - Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes

AU - Inceoglu, Bora

AU - Wagner, Karen M.

AU - Yang, Jun

AU - Bettaieb, Ahmed

AU - Schebb, Nils H.

AU - Hwang, Sung Hee

AU - Morisseau, Christophe

AU - Haj, Fawaz

AU - Hammock, Bruce D.

PY - 2012/7/10

Y1 - 2012/7/10

N2 - The nerve damage occurring as a consequence of glucose toxicity in diabetes leads to neuropathic pain, among other problems. This pain dramatically reduces the quality of life in afflicted patients. The progressive damage to the peripheral nervous system is irreversible although strict control of hyperglycemia may prevent further damage. Current treatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity of the pain state. However, available therapeutics have drawbacks, arguing for the need to better understand the pathophysiology of neuropathic pain and develop novel treatments. Here we demonstrate that stabilization of a class of bioactive lipids, epoxygenated fatty acids (EpFAs), greatly reduces allodynia in rats caused by streptozocin-induced type I diabetes. Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the levels of plasma and spinal EpFAs, respectively, and generated dose-dependent antiallodynic effects more potently and efficaciously than gabapentin. In acute experiments, positive modulation of EpFAs did not display differences in insulin sensitivity, glucose tolerance, or insulin secretion, indicating the efficacy of sEHIs are not related to the glycemic status. Quantitative metabolomic analysis of a panel of 26 bioactive lipids demonstrated that sEHI-mediated antiallodynic effects coincided with a selective elevation of the levels of EpFAs in the plasma, and a decrease in degradation products coincided with the dihydroxy fatty acids in the spinal cord. Overall, these results argue that further efforts in understanding the spectrum of effects of EpFAs will yield novel opportunities in treating neuropathic pain.

AB - The nerve damage occurring as a consequence of glucose toxicity in diabetes leads to neuropathic pain, among other problems. This pain dramatically reduces the quality of life in afflicted patients. The progressive damage to the peripheral nervous system is irreversible although strict control of hyperglycemia may prevent further damage. Current treatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity of the pain state. However, available therapeutics have drawbacks, arguing for the need to better understand the pathophysiology of neuropathic pain and develop novel treatments. Here we demonstrate that stabilization of a class of bioactive lipids, epoxygenated fatty acids (EpFAs), greatly reduces allodynia in rats caused by streptozocin-induced type I diabetes. Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the levels of plasma and spinal EpFAs, respectively, and generated dose-dependent antiallodynic effects more potently and efficaciously than gabapentin. In acute experiments, positive modulation of EpFAs did not display differences in insulin sensitivity, glucose tolerance, or insulin secretion, indicating the efficacy of sEHIs are not related to the glycemic status. Quantitative metabolomic analysis of a panel of 26 bioactive lipids demonstrated that sEHI-mediated antiallodynic effects coincided with a selective elevation of the levels of EpFAs in the plasma, and a decrease in degradation products coincided with the dihydroxy fatty acids in the spinal cord. Overall, these results argue that further efforts in understanding the spectrum of effects of EpFAs will yield novel opportunities in treating neuropathic pain.

KW - Analgesic drug

KW - Cytochrome P450

KW - Glucose homeostasis

KW - Motor depressant

KW - Soluble epoxide hydrolase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84863957642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863957642&partnerID=8YFLogxK

U2 - 10.1073/pnas.1208708109

DO - 10.1073/pnas.1208708109

M3 - Article

C2 - 22733772

AN - SCOPUS:84863957642

VL - 109

SP - 11390

EP - 11395

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 28

ER -